Search Results - Changhoon Yoo
- Showing 1 - 20 results of 36
- Go to Next Page
-
1
-
2
-
3
-
4
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker an... by Changhoon Yoo, Min‐Hee Ryu, Young-Soon Na, Baek‐Yeol Ryoo, Chae-Won Lee, Yoon‐Koo Kang
Published 2016Artigo -
5
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients by Bum Jun Kim, Changhoon Yoo, Kyu‐pyo Kim, Jaewon Hyung, Seongjoon Park, Baek‐Yeol Ryoo, Heung-Moon Chang
Published 2017Artigo -
6
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen by Changhoon Yoo, Bum Jun Kim, Kyu‐pyo Kim, Jae‐Lyun Lee, Tae Won Kim, Baek‐Yeol Ryoo, Heung-Moon Chang
Published 2016Artigo -
7
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospec... by Jaekyung Cheon, Shigeo Shimose, Hyung‐Don Kim, Takashi Niizeki, Min‐Hee Ryu, Tomotake Shirono, Baek‐Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo
Published 2025Artigo -
8
-
9
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors by Changhoon Yoo, Ángela Lamarca, Hye Jin Choi, Arndt Vogel, Michael J. Pishvaian, Lipika Goyal, Makoto Ueno, Angela Märten, Michael Teufel, Lijiang Geng, Chigusa Morizane
Published 2024Artigo -
10
Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors by Joo Young Kim, Jisup Kim, Yong-il Kim, Dong‐Hoon Yang, Changhoon Yoo, In Ja Park, Baek‐Yeol Ryoo, Jin‐Sook Ryu, Seung‐Mo Hong
Published 2024Artigo -
11
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer by Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, Masatoshi Kudo, Makoto Ueno, Shunsuke Kondo, Li-Tzong Chen, Motonobu Osada, Christoph Helwig, Isabelle Dussault, Masafumi Ikeda
Published 2020Artigo -
12
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma by Changhoon Yoo, Joong‐Won Park, Yoon Jun Kim, Do Young Kim, Su Jong Yu, Tae Seop Lim, Su Jin Lee, Baek‐Yeol Ryoo, Ho Yeong Lim
Published 2018Artigo -
13
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis by Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang, Neung Hwa Park, Jung Woo Shin, Kang Mo Kim, Han Chu Lee, Joo‐Ho Lee, Changhoon Yoo, Baek‐Yeol Ryoo
Published 2020Artigo -
14
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib by Y-K. Kang, Changhoon Yoo, B-Y. Ryoo, J J Lee, Eugene Tan, Inkeun Park, J H Park, Yoon Ji Choi, Jungmin Jo, J.-S. Ryu, M.H. Ryu
Published 2013Artigo -
15
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, pha... by Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo, Baek‐Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung‐Ho Nam, Nikhil H. Ramaiya, Jyothi P. Jagannathan, George D. Demetri
Published 2013Artigo -
16
Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study by Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Changhoon Yoo, Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, Jonggi Choi
Published 2020Artigo -
17
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer by Changhoon Yoo, Jenn-Jiang Hwang, Je Hyeong Kim, T W Kim, J S Lee, D H Park, S S Lee, Dong Wan Seo, S K Lee, MH Kim, Dongjin Han, Sung‐Cheol Kim, Jia-Lin Lee
Published 2009Artigo -
18
-
19
<i>Chlamydia psittaci</i> infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea by Changhoon Yoo, Min‐Hee Ryu, Jooryung Huh, Ji Hyun Park, Hye Jin Kang, Hyo Sook Ahn, Yongjae Lee, Myoung Joon Kim, Hyoungnam Lee, Tae Won Kim, Heung Moon Chang, Jae‐Lyun Lee, Yoon‐Koo Kang
Published 2007Artigo -
20
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials by Changhoon Yoo, Anna Saborowski, Jaewon Hyung, Patrick Wenzel, Il Hwan Kim, Henning Wege, Kyu‐pyo Kim, Gunnar Folprecht, Baek‐Yeol Ryoo, Phillip Schütt, Jaekyung Cheon, Thorsten Oliver Goetze, Hyewon Ryu, Ji Sung Lee, Arndt Vogel
Published 2025Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Oncology
Cancer
Gastroenterology
Chemotherapy
Gemcitabine
Colorectal cancer
Immunotherapy
Surgery
Hepatocellular carcinoma
Pancreatic cancer
Confidence interval
Nivolumab
Adverse effect
Cancer research
Clinical endpoint
Oxaliplatin
Clinical trial
Hazard ratio
Immunology
Sorafenib
Atezolizumab
Bevacizumab
Biliary tract
Cisplatin
Lenvatinib
Pathology
Adenocarcinoma
Biliary tract cancer